Now Available with SB-1
Added MD Protection with Addition of Serotype 2 Mareks Virus
Ultifend® is a vaccine consisting of an HVT virus which expresses the VP2 gene of the Infectious Bursal Disease virus (IBD) and the F gene of the Newcastle Disease virus (ND).
ULTIFEND® IBD ND was selected from among 40 different vaccine candidates as the best construct for optimal protection against IBD, ND and Marek’s disease. Construct 3 was selected based on similar ND protection as VECTORMUNE® ND and similar IBD protection as rHVT/VP2 STC.
ULTIFEND® IBD ND + SB-1 contains a genetically engineered Marek’s disease vaccine of serotype 3 (turkey herpesvirus or HVT) expressing infectious bursal disease and Newcastle disease key protective antigens, and a serotype 2 (SB-1) Marek’s disease vaccine. This bivalent Marek’s disease vaccine containing serotypes 2 and 3 is presented in a frozen cell associated form in 2 ampoules. One ampoule contains the HVT IBD ND fraction and one ampoule contains the SB-1 fraction. The cells and virus particles are very fragile and require careful handling to prevent damage or loss of titer in order to achieve optimum efficacy. The vaccine is stored and shipped in frozen form in liquid nitrogen.
The IBV virus is also characterized by its capacity to mutate. Variant IBV strains are continually emerging and breaking through conventional vaccine regimens, creating the need for additional safe and efficacious commercial vaccines. Among the variants currently circulating in the US, Georgia 08 (GA08) and Georgia 13 (GA13), both with respiratory tropism, and DMV/1639/11, a nephropathogenic virus originally isolated from the Delmarva Peninsula, are major concerns for chicken producers.
ULTIFEND® IBD ND + RISPENS Live HVT vector IBD & ND vaccine in combination with conventional live Rispens Serotype 1 Marek’s.
IBD Protection ND Protection
IBD Protection
ULTIFEND® IBD ND at minimum protective dose achieved the 9 CFR requirement of at least 90% protection from standard IBD lesions.
Eighteen days old embryos were vaccinated via in ovo or day of age chickens were vaccinated via subcutaneous and challenged at 5 weeks of age with IBDV-STC challenge strain via eye-drop, according to 9 CFR. Necropsy to score for bursa lesions were performed to evaluate the percent protection of the vaccinates in comparison to non-placebo-vaccinated chickens (Study on file with CVB).
ND Protection
ULTIFEND® IBD ND at minimum protective dose achieved the 9 CFR requirement of at least 90% protection from mortality induced by ND virus infection.
Eighteen days old embryos were vaccinated via in ovo or day of age chickens were vaccinated via subcutaneous and challenged at 4 weeks of age with Texas GB via IM injection according to 9 CFR (Study of file with CVB).
Marek’s Disease Protection
ULTIFEND® IBD ND at minimum protective dose achieved the 9 CFR requirement of at least 80% protection from tumor lesions caused by virulent GA Marek’s Disease virus.
Eighteen days old embryos were vaccinated via in ovo or day of age chickens were vaccinated via subcutaneous and challenged at 5 days of age with virulent Marek’s disease virus GA strain according to 9 CFR (Study on file with CVB).